scispace - formally typeset
M

Mohamed F. El Shehry

Publications -  6
Citations -  232

Mohamed F. El Shehry is an academic researcher. The author has contributed to research in topics: Pyrazole & Thiazole. The author has an hindex of 5, co-authored 5 publications receiving 131 citations.

Papers
More filters
Journal ArticleDOI

Quinoline derivatives bearing pyrazole moiety: Synthesis and biological evaluation as possible antibacterial and antifungal agents

TL;DR: The synthesized quinoline derivatives bearing pyrazole moiety are interesting scaffolds for the development of novel antibacterial and antifungal agents according to the tested strains of bacteria and fungi.
Journal ArticleDOI

Novel structural hybrids of quinoline and thiazole moieties: Synthesis and evaluation of antibacterial and antifungal activities with molecular modeling studies.

TL;DR: One of the best ways to design new biocidal agents is synthesizing hybrid molecules by combining two or more bioactive moieties in a single molecular scaffold, so quinolines bearing a thiazole moiety can be suggested as interesting scaffolds for the development both of the novel antibacterial and antifungal agents.
Journal ArticleDOI

Synthesis of pyrazoles containing benzofuran and trifluoromethyl moieties as possible anti-inflammatory and analgesic agents

TL;DR: In this article, a series of novel pyrazoles containing benzofuran and trifluoromethyl moieties were synthesized via two routes starting from 5-(3-(trifluorsyl)phenyl azo) salicylaldehyde.
Journal ArticleDOI

Design, synthesis and biological evaluation of quinoxaline N -propionic and O -propionic hydrazide derivatives as antibacterial and antifungal agents

TL;DR: It is suggested that quinaxoline derivatives bearing a pyrazole moiety are interesting scaffolds for the development of novel antibacterial and antifungal agents.
Journal ArticleDOI

New Biguanides as Anti-Diabetic Agents, Part II: Synthesis and Anti-Diabetic Properties Evaluation of 1-Arylamidebiguanide Derivatives as Agents of Insulin Resistant Type II Diabetes.

TL;DR: Oral treatment of hyperglycemic rats with the synthesized biguanide derivatives showed a significant decrease of the elevated glucose in comparison with the anti‐diabetic standard drug, metformin.